Streetbeat News

NVCR

NovoCure Limited

https://www.novocure.com

Industry

Medical - Instruments & Supplies

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Open

15.54

Mkt cap

1.8B

Volume

686K

High

16.55

P/E Ratio

-11.86

52-wk high

24.73

Low

15.35

Div yield

N/A

52-wk low

11.29

NovoCure (NASDAQ:NVCR) reported Q2 losses of $(0.54) per share, missing the analyst consensus estimate of $(0.50) by 8 percent. This is a 134.78 percent increase in losses from the same period last year. However, the company's quarterly sales of $126.05 million beat the analyst consensus estimate of $124.26 million by 1.44 percent, despite a 10.52 percent decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 11:03 am

NovoCure (NASDAQ:NVCR) is set to release its quarterly earnings report on July 27, 2023. Analysts estimate an earnings per share (EPS) of -$0.50. The company's past performance shows a mixed trend of beating and missing EPS estimates, which has led to varied stock price changes. The company's shares are currently trading at $38.97, down 42.65% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 8:02 pm

On Monday, 70 companies hit new 52-week lows. Estee Lauder Cos was the largest firm by market cap to set a new 52-week low, while 9 Meters Biopharma was the smallest. AppHarvest was the biggest loser, trading down 70.3% to reach its 52-week low, while SWK Holdings was the biggest winner, with shares trading up 0.0% after rebounding from its new 52-week low.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 7:48 pm

On Friday, 54 companies hit new 52-week lows. The largest company in terms of market cap to set a new 52-week low was NovoCure (NASDAQ:NVCR), while the smallest was Ucommune International (NASDAQ:UK). Sigma Additive Solutions (NASDAQ:SASI) saw the largest move, with shares plummeting 27.56%. Greenbrook TMS (NASDAQ:GBNH) shares were the most resilient, moving up 0.0% in response to hitting its 52-week low.

Portfolio Pulse from Benzinga Insights

July 21, 2023 | 5:24 pm

Novocure has received a positive recommendation from an independent data monitoring committee to continue its Phase 3 PANOVA-3 trial. The trial is evaluating the effectiveness of Tumor Treating Fields Therapy in treating pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:02 pm

During Thursday's session, 40 stocks hit new 52-week lows. The largest company by market cap to set a new 52-week low was Crown Castle (NYSE:CCI), while the smallest was Ucommune International (NASDAQ:UK). Vir Biotechnology (NASDAQ:VIR)'s stock fell the most, down 44.38%, while Yunji (NASDAQ:YJ)'s stock rebounded the most, trading up 0.0% after dropping to a new 52-week low.

Portfolio Pulse from Benzinga Insights

July 20, 2023 | 6:01 pm

On Monday, 50 companies reached new 52-week lows. The biggest company by market cap to set a new 52-week low was Verizon Communications (NYSE:VZ), while the smallest was Galmed Pharmaceuticals (NASDAQ:GLMD). Novan (NASDAQ:NOVN) was the biggest loser of the morning session, dropping 72.16% to reach its new 52-week low. Cal-Maine Foods (NASDAQ:CALM) shares were the most resilient, rising 0.06% from its new 52-week low.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 4:17 pm

Benzinga's options activity scanner has identified unusual trading activity in 10 health care stocks. The stocks include Pfizer (PFE), Novocure (NVCR), Tilray (TLRY), Teladoc Health (TDOC), Align Technology (ALGN), UnitedHealth Group (UNH), Eli Lilly and Company (LLY), Karuna Therapeutics (KRTX), Abbott Laboratories (ABT), and Quidel Corporation (QDEL). The scanner tracks large transactions, known as 'whale alerts', which can indicate the sentiment of large investors and potentially predict market movements.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 5:39 pm

On Wednesday, 29 companies set new 52-week lows, with NovoCure being the largest in terms of market cap and HTG Molecular Diagnostics being the smallest. PolarityTE's stock fell the most, while Owlet's shares rebounded the highest.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 4:38 pm

Piper Sandler analyst Jason Bednar maintains a Neutral rating on NovoCure (NASDAQ:NVCR) and lowers the price target from $67 to $62.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.